Cover Image

Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancer

Introduction: - We investigated the single-nucleotide polymorphism C-938A in the apoptotic gene BCL-2 to assess the potential impact as a genetic marker for response to chemotherapy and outcome prediction in small cell lung cancer (SCLC) patients. Such a marker might help optimize lung cancer treatm...

Full description

Saved in:
Bibliographic Details
Main Authors: Knöfel, Lena Franziska (Author) , Werle-Schneider, Gisela (Author) , Dally, Heike (Author) , Müller, Phillip (Author) , Edler, Lutz (Author) , Bartsch, Helmut (Author) , Tuengerthal, Siegfried (Author) , Heußel, Claus Peter (Author) , Reinmuth, Niels (Author) , Thomas, Michael (Author) , Risch, Angela (Author)
Format: Article (Journal)
Language:English
Published: 2011
In: Journal of thoracic oncology
Year: 2011, Volume: 6, Issue: 1, Pages: 183-189
ISSN:1556-1380
DOI:10.1097/JTO.0b013e3181f8a20e
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/JTO.0b013e3181f8a20e
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086415319146
Get full text
Author Notes:Lena Franziska Knoefel, Gisela Werle-Schneider, Heike Dally, Phillip Johannes Müller, Lutz Edler, Helmut Bartsch, Siegfried Tuengerthal, Claus Peter Heussel, Niels Reinmuth, Michael Thomas, and Angela Risch
Description
Summary:Introduction: - We investigated the single-nucleotide polymorphism C-938A in the apoptotic gene BCL-2 to assess the potential impact as a genetic marker for response to chemotherapy and outcome prediction in small cell lung cancer (SCLC) patients. Such a marker might help optimize lung cancer treatment in a tailored approach. - Methods: - DNA derived from peripheral blood lymphocytes of 188 Caucasian SCLC patients treated at the Thoraxklinik Heidelberg was genotyped. Chemotherapy response, time to progression (TTP), and overall survival (OS) were evaluated using multivariable regression (unconditional logistic for response and Cox proportional hazard for TTP and OS) with odds ratios and hazard ratios (HRs) and their 95% confidence intervals (CIs) as quantitative outcome measures, respectively. - Results: - Small cell lung cancer patients carrying the BCL-2 -938CC genotype showed significantly worse TTP than patients carrying the BCL-2 -938AA genotype (HR = 1.86; 95% CI = 1.10-3.13, p = 0.021). The same adverse effect was shown for OS (HR = 2.38; 95% CI = 1.38-4.12, p = 0.002). Also, patients with limited disease (HR = 2.57; 95% CI = 1.18-5.60, p = 0.017) showed worse OS with the BCL-2 -938CC genotype. - Conclusion: - BCL-2 -938CC genotype shows significantly worse outcome in small cell lung cancer patients. This genetic marker might particularly impact on treatment strategies using BCL-2 antisense approaches.
Item Description:Available online 20 November 2015
Gesehen am 10.10.2022
Physical Description:Online Resource
ISSN:1556-1380
DOI:10.1097/JTO.0b013e3181f8a20e

Similar Items